Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort

BACKGROUND: Tenofovir alafenamide (TAF)-containing combinations were introduced in Switzerland after October 2016 and are recommended over tenofovir disoproxil fumarate (TDF) in patients with osteoporosis or impaired renal function. METHODS: We included all participants of the Swiss HIV Cohort Study...

Descripción completa

Detalles Bibliográficos
Autores principales: Surial, Bernard, Cavassini, Matthias, Calmy, Alexandra, Fehr, Jan, Stöckle, Marcel, Bernasconi, Enos, Roth, Bianca, Fux, Christoph A., Kovari, Helen, Furrer, Hansjakob, Rauch, Andri, Wandeler, Gilles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6785894/
https://www.ncbi.nlm.nih.gov/pubmed/31601174
http://dx.doi.org/10.1186/s12879-019-4454-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6785894/
https://www.ncbi.nlm.nih.gov/pubmed/31601174
http://dx.doi.org/10.1186/s12879-019-4454-9

Ejemplares similares